Unit of Toxicology, University Center of Legal Medicine, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland.
Anal Bioanal Chem. 2010 Apr;396(7):2523-32. doi: 10.1007/s00216-009-3412-6. Epub 2010 Jan 10.
The objective of this work was to combine the advantages of the dried blood spot (DBS) sampling process with the highly sensitive and selective negative-ion chemical ionization tandem mass spectrometry (NICI-MS-MS) to analyze for recent antidepressants including fluoxetine, norfluoxetine, reboxetine, and paroxetine from micro whole blood samples (i.e., 10 microL). Before analysis, DBS samples were punched out, and antidepressants were simultaneously extracted and derivatized in a single step by use of pentafluoropropionic acid anhydride and 0.02% triethylamine in butyl chloride for 30 min at 60 degrees C under ultrasonication. Derivatives were then separated on a gas chromatograph coupled with a triple-quadrupole mass spectrometer operating in negative selected reaction monitoring mode for a total run time of 5 min. To establish the validity of the method, trueness, precision, and selectivity were determined on the basis of the guidelines of the "Société Française des Sciences et des Techniques Pharmaceutiques" (SFSTP). The assay was found to be linear in the concentration ranges 1 to 500 ng mL(-1) for fluoxetine and norfluoxetine and 20 to 500 ng mL(-1) for reboxetine and paroxetine. Despite the small sampling volume, the limit of detection was estimated at 20 pg mL(-1) for all the analytes. The stability of DBS was also evaluated at -20 degrees C, 4 degrees C, 25 degrees C, and 40 degrees C for up to 30 days. Furthermore, the method was successfully applied to a pharmacokinetic investigation performed on a healthy volunteer after oral administration of a single 40-mg dose of fluoxetine. Thus, this validated DBS method combines an extractive-derivative single step with a fast and sensitive GC-NICI-MS-MS technique. Using microliter blood samples, this procedure offers a patient-friendly tool in many biomedical fields such as checking treatment adherence, therapeutic drug monitoring, toxicological analyses, or pharmacokinetic studies.
本研究旨在结合干血斑(DBS)采样过程的优势和高灵敏度、高选择性的负离子化学电离串联质谱(NICI-MS-MS)分析方法,从微量全血样品(即 10 μL)中检测包括氟西汀、去甲氟西汀、瑞波西汀和帕罗西汀在内的新型抗抑郁药。在分析之前,DBS 样本被打孔,然后在 60°C 下超声处理 30 分钟,同时使用五氟丙酸酐和 0.02%三乙胺在正丁烷中进行一步提取和衍生化。衍生产物随后在气相色谱仪上与三重四极杆质谱仪联用,在负选择反应监测模式下运行 5 分钟进行分离。为了验证方法的有效性,根据“法国药品科学技术学会(SFSTP)”的指南确定了方法的准确度、精密度和选择性。研究发现,氟西汀和去甲氟西汀的浓度范围在 1 至 500ng/mL 之间,瑞波西汀和帕罗西汀的浓度范围在 20 至 500ng/mL 之间呈线性关系。尽管采样量很小,但所有分析物的检测限估计为 20pg/mL。还评估了 DBS 在-20°C、4°C、25°C 和 40°C 下长达 30 天的稳定性。此外,该方法还成功应用于健康志愿者口服单剂量 40mg 氟西汀后的药代动力学研究。因此,这种经过验证的 DBS 方法结合了提取-衍生化的单一步骤和快速灵敏的 GC-NICI-MS-MS 技术。使用微升血液样本,该程序为许多生物医学领域提供了一种方便患者的工具,例如检查治疗依从性、治疗药物监测、毒理学分析或药代动力学研究。